RT Journal Article SR Electronic T1 Vibrio Cholerae O1 Transmission in Bangladesh: Insights from a Nationally-Representative Serosurvey JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.03.13.20035352 DO 10.1101/2020.03.13.20035352 A1 Azman, Andrew S A1 Lauer, Stephen A1 Rahman Bhuiyan, M. Taufiqur A1 Luquero, Francisco J A1 Leung, Daniel T A1 Hegde, Sonia A1 Harris, Jason A1 Paul, Kishor Kumar A1 Khaton, Fatema A1 Ferdous, Jannatul A1 Lessler, Justin A1 Salje, Henrik A1 Qadri, Firdausi A1 Gurley, Emily S YR 2020 UL http://medrxiv.org/content/early/2020/03/16/2020.03.13.20035352.abstract AB Background Pandemic Vibrio cholerae from cholera-endemic countries around the Bay of Bengal regularly seed epidemics globally. Without reducing cholera in these countries, including Bangladesh, global cholera control may never be achieved. Little is known about the geographic distribution and magnitude of V. cholerae O1 transmission nationally. Here we use recent advances in cholera seroepidemiology to describe infection risk across Bangladesh overcoming many of the limitations of current clinic-based surveillance.Methods We tested serum from a nationally-representative serosurvey in Bangladesh of 2,778 participants with eight V. cholerae-specific assays. Using these data with a previously validated machine learning model we estimate the annual seroincidence rate and use Bayesian geostatistical models to create high-resolution national maps of infection risk.Findings We estimate a national seroincidence rate of 19.1% (95% CI 12.2-26.9%). Our high-resolution maps reveal large heterogeneity of infection risk, with community-level annual infection risk within the sampled population ranging from 2.4-69.0%. Across the country, we estimate that 31.0 million (95% CI 19.8-43.7 million) occurred in the year before the survey with most of these infections occurring in urban areas, including Dhaka, the capital.Interpretation Serosurveillance provides an avenue for identifying areas with high V. cholerae O1 transmission and exploring key risk factors for infection across geographic scales. This may serve as an important tool for countries to plan and monitor progress towards 2030 cholera elimination goals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunded by The Bill and Melinda Gates Foundation, National Institutes of Health and United States Centers for Disease ControlAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and source code to reproduce analyses are available at https://github.com/HopkinsIDD/Bangladesh-Cholera-Serosurvey https://github.com/HopkinsIDD/Bangladesh-Cholera-Serosurvey